Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer

✍ Scribed by K. M. W. Pisters; M. G. Kris; R. J. Gralla; B. Hilaris; P. M. McCormack; M. S. Bains; N. Martini

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 558 KB
• Volume: 56
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930560407

✦ Synopsis

This prospective randomized trial was performed to determine whether postoperative chemotherapy with vindesine and cisplatin could lengthen time to progression and overall survival in stage I11 (Tl-3N2MO) non-small cell lung cancer (NSCLC) patients. Seventy-two patients were entered; 36 were randomized to receive chemotherapy. Patients were stratified by extent of resection (complete vs. incomplete) and histology (squamous vs. nonsquamous). All had surgery and mediastinal irradiation 6 7 weeks post-thoracotomy . Incompletely resected patients had intraoperative Iz5I and/or 1921r implantation. Vindesine (3 mg/m2) weekly X 5 , then every 2 weeks X 8, and cisplatin (1 20 mg/m2) days 1, 29, 7 1, 1 13 were planned for those randomized to chemotherapy. No difference in time to progression (median 9.2 months for radiation + chemotherapy vs. 9.0 months for radiation, P = 0.35) or overall survival (16.3 months for radiation + chemotherapy vs. 19.1 months for radiation, P = 0.42) was found. Postoperative vindesine and cisplatin did not prolong time to progression or survival in this population of stage I11 NSCLC.